The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
The Oxford Science Park (OSP), located on the southern edge of Oxford and owned by Magdalen College, Oxford, is entering a significant new phase of expansion aimed at strengthening the UK’s life sciences and technology infrastructure. This growth is driven by strong...
The life science sector encompassing pharmaceuticals, biotechnology, medical technologies, diagnostics and related services is evolving rapidly. Success in this industry no longer rests solely on scientific discovery. Increasingly it depends on the right talent,...
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
London, Oxford and Cambridge have long been the heartlands of the UK life sciences sector, but other regions across the country are now rapidly emerging as centres of innovation. The Midlands, the North of England, Scotland and Northern Ireland are developing strong...
In late September 2025, former U.S. President Donald J. Trump revived a series of controversial health claims and policy proposals concerning women especially pregnant women and children, triggering sharp pushback from medical experts, public health authorities, and...
Walking around 7,000 steps each day could help sharpen cognition and shield against a variety of chronic illnesses, according to a major new analysis. This target may be more attainable, yet still effective, than the widely publicised 10,000 step goal. Published in...
The NHS in England is leading the world as the first healthcare system to introduce a pioneering ‘trojan horse’ therapy for patients with blood cancer, offering the potential to delay disease progression nearly three times longer than current treatment options....